Juno Therapeutics has appointed Jay Flatley to its board of directors. He currently serves as executive chairman of Illumina and as the chair for the board of directors of Illumina's subsidiary, Helix. He also serves an advisory board member for UC San Diego's Moore Cancer Center, serves as the board of directors at Coherent and Denali, and is on the board of trustees of the Salk Institute. Previously, he served as CEO of Illumina from 1999 to 2016. Before Illumina, he served as president and CEO of Molecular Dynamics, later acquired by Amersham Pharmacia Biotech and now a part of GE Healthcare.